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Abstract
Objective To compare the effects of five years of specialised early
intervention (SEI) treatment for first episode schizophrenia spectrum
disorder with the standard two years of SEI plus three years of treatment
as usual.
DesignRandomised, superiority, parallel group trial with blinded outcome
assessment. Randomisation was centralised and computerised with
concealed randomisation sequence carried out at an external site.
Setting Participants were recruited from six OPUS teams in Denmark
between 2009 and 2012. OPUS teams provide SEI treatment to all
patients diagnosed with a schizophrenia spectrum disorder in Denmark.
Participants 400 participants (51% women) with a mean age of 25.6
(standard deviation 4.3) were randomised to five years of SEI
(experimental intervention; n=197) or to two years of SEI plus three
years of treatment as usual (control; n=203).
Interventions OPUS treatment consists of three core
elements—modified assertive community treatment, family involvement,
and social skill training—with a patient-case manager ratio of no more
than 12:1. For participants randomised to five years of OPUS treatment,
the treatment was largely unchanged. Participants randomised to the
control group were mostly referred to community health centres after
two years of SEI treatment.
Main outcomes Follow-up assessments were conducted five years
after start of OPUS treatment. Primary outcome was negative symptoms
measured on the scale for assessment of negative symptoms
(avolition-apathy, anhedonia, alogia, and affective blunting). Secondary
outcomes were remission of both negative and psychotic symptoms,
psychotic symptoms, suicidal ideation, substance abuse, compliance
with medical treatment, adherence with treatment, client satisfaction,
days in hospital care, and labour market affiliation.
Results Levels of negative symptoms did not differ between the
intervention group and control group (1.72 v 1.81 points; estimated mean
difference −0.10 (95% confidence interval 0.33 to 0.13), P=0.39).
Participants receiving five years of OPUS treatment were more likely to
remain in contact with specialised mental health services (90.4% v
55.6%, P<0.001), had higher client satisfaction (estimated mean
difference 2.57 points (95% confidence interval 1.36 to 3.79), P<0.001),
and had a stronger working alliance (estimated mean difference 5.56
points (95% confidence interval 2.30 to 8.82), P=0.001) than the control
group.
Conclusions This trial tests SEI treatment for up to five years for patients
with first episode schizophrenia spectrum disorder; previous trials have
found treatment effects for programmes lasting from one to three years.
The prolonged SEI treatment had few effects, which could be due to the
high level of treatment provided to control participants and the late start
of specialised treatment.
Trial registration Clinicaltrial.gov NCT00914238.
Correspondence to: N Albert Nikolai.albert@regionh.dk
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Introduction
The most successful addition to the treatment of schizophrenia
and other psychotic illnesses seen over recent decades has been
the introduction of specialised early intervention (SEI).1 2 The
SEI teams combine assertive community treatment,3 4
psychoeducation,5 and family involvement,6 7 with a low case
load of patients for case managers. The early intervention
paradigm from which the SEI teams grew is based on the
hypothesis of a critical period in the disorder.8-10 This hypothesis
suggests that the more fluctuating course seen early in psychotic
disorders should be more receptive to intervention, which could
have long term effects if patients could be stabilised at a lower
level of disability. This led early intervention advocates to argue
that treatment resources and research should be directed toward
the early phase of illness.
SEI teams are now well established as standard treatment for
first episode psychosis in many developed countries.11 12 A
meta-analysis of the effect of SEI teams published in 201413
identified four randomised clinical trials testingmultidisciplinary
teams providing assertive treatment combined with
psychoeducation and family interventions for one to two years.
This analysis showed that the SEI teams had positive effects on
hospital admission rates and use of bed days as long as patients
were in treatment. For the trials with long term follow-up after
the end of the intervention period, the results were more
contradictory.14-16 The largest randomised clinical trial of SEI
treatment, the OPUS I trial,3-17 found that participants in the
intervention group relapsed to the psychopathological and
functional levels of the control participants three years after the
end of the intervention.15 In a naturalistic study from Canada,
researchers testing the effect of five years of SEI treatment found
that they could sustain and further reduce the psychopathology
and increase the functional level of the participants.18
There is currently a gap in knowledge regarding how to improve
the long term effects of SEI programmes. Based on current
evidence, it seems fair to hypothesise that SEI teams have an
effect as long as patients are in treatment. We therefore aimed
to test whether the positive results seen in patients receiving
SEI treatment can be sustained if the treatment is prolonged.
Given the previous findings of positive effect of the SEI
treatment17 19 and the limited pharmacological treatment options
for negative symptoms, we tested whether negative symptoms
are reduced in a patients receiving prolonged SEI treatment
compared with those treated in community health centres after
termination of two years of SEI treatment.
Methods
Participants
All participants were recruited from six Danish OPUS teams
(five in Copenhagen and one in Aarhus) between 2009 and
2012. They were recruited an average of 19 months into their
24 month treatment programme. OPUS teams are part of the
adult psychiatric services treating patients aged 18-35 at the
time of their first diagnosis of schizophrenia spectrum disorder
(ICD-10 (international classification of diseases, 10th revision):
schizophrenia F20, schizotypal disorder F21, persistent
delusional disorders F22, acute and transient psychotic disorders
F23, induced delusional disorder F24, schizoaffective disorders
F25, other non-organic psychotic disorders F28, and unspecified
non-organic psychosis F29).20 Participants had to meet the
diagnostic criteria for one of the above mentioned diagnoses at
time of inclusion. Patients with an IQ below 70 points are not
treated in OPUS teams and therefore were not part of the study
population.
Design and randomisation
The study was a randomised, superiority, parallel group trial
with blinded outcome assessment, comparing five years of SEI
treatment versus the standard two year SEI treatment
(clinicaltrial.gov NCT00914238). All participants received two
years of SEI treatment in an OPUS team. Nineteen months into
the programme, participants were assessed for inclusion into
the present trial. After assessment, the participants were
randomised to continue in the OPUS team for three additional
years (that is, five years in total) versus discontinuation after
the standard two years.21 The randomisation was centralised and
computerised with concealed randomisation sequence carried
out by the Copenhagen trial unit (CTU). Block sizes ranging
between 10 and 6 were concealed to clinicians and investigators.
Randomisation was stratified according to treatment site and
negative symptoms. Negative symptoms were assessed for the
four negative global domains (avolition-apathy, anhedonia,
alogia, and affective blunting) on the scale for assessment of
negative symptoms,22 and stratified by one or more domains
with a score of 3 or above, compared with no scores of 3 or
above. The full study protocol is published elsewhere.21
OPUS treatment
The SEI treatment provided in Denmark is namedOPUS. OPUS
treatment is a psychosocial treatment programme provided to
all patients diagnosed with a schizophrenia spectrum disorder
in Denmark. The treatment is provided for the first two years
after initial diagnosis. The treatment programmewas established
after the OPUS I trial proved the treatment’s effectiveness in
reducing both negative and psychotic symptoms.17 19
The treatment had three main pillars: modified assertive
treatment,23 family involvement,24 25 and social skill training.5
In addition, the patient could, in groups or individually, receive
different recovery programmes tailored to personal need. At the
start of treatment, the teams tried to establish contact with at
least one family member who would then be invited to attend
educational workshops and psychoeducational groups.7 The
multidisciplinary teams include psychiatrists, psychologists,
nurses, social workers, physiotherapists, and vocational
therapists. All team members, except for the psychiatrist,
function as casemanagers. The ratio of patients to casemanagers
must not exceed 12:1. For the participants randomised to
extended OPUS treatment, there were nomajor changes in their
treatment programmes. More participants were expected to be
in remission, so the ratio of patients to case managers was raised
to 15:1. All treatment and group programmes were available
for the participants, and the families were invited back for a
psychoeducational booster session.
Treatment as usual (years 2-5)
Patients randomised to treatment as usual after two years of
OPUS treatment would most often be referred to a community
health centre. Alternatively, if they no longer were considered
in need of specialised treatment, participants could be referred
to the primary care of their general practitioner or to assertive
community treatment if they were in need of more intensive
treatment than the community health centres could provide. The
assertive community teams treat patients who are unable to
attend office meetings. Estimates from the capital region, where
three quarters of the participants were treated, found that 19%
(n=31) of participants randomised to treatment as usual were
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in contact with an assertive community team at some point
during follow-up. In community health centres, home visits
were possible; however, owing to the higher ratio of patients to
case managers (typically between 20:1 and 30:1), the standard
was office meetings at outpatient treatment facilities.
Antipsychotic treatment
Participants in both intervention groups were treated in
accordance with national and regional guidelines recommending
low doses of antipsychotic drugs in monotherapy for patients
with first episode schizophrenia spectrum disorder and second
generation antipsychotic drugs as first line of treatment.26 27 The
medical treatment was not part of the intervention and no fixed
protocol exists. A national quality database monitors the use of
antipsychotic drugs, but data on individual participants were
not accessible.
Outcomes
Primary and secondary outcomes are listed at clinicaltrial.gov
NCT00914238. Interviews were conducted either at research
facilities in Copenhagen and Aarhus or at the patient’s home.
Follow-up interviews were conducted five years after the start
in OPUS treatment, from November 2012 to June 2015. The
intervention group had then received five years of OPUS
treatment while the control group had received two years of
OPUS treatment followed by three years of treatment as usual.
Outcome assessors were blind to treatment allocation and high
priority was given to keeping the investigator blinded during
the follow-up interview. Thus, all questions regarding the
treatment were presented in self-rated questionnaires.
Main diagnoses and comorbidity were based on the schedule
for clinical assessment in neuropsychiatry (SCAN2.1),28 sections
6-8, 11, 12, and 17-19. Duration of untreated psychosis was
assessed at baseline by use of an adjusted version of the
interview for the retrospective assessment of the onset of
schizophrenia.29 In addition to study outcomes, data on
sociodemographic and previous psychiatric illness were
collected. Educational level was split into short and long
education. Short education included upper secondary education,
post-secondary non-tertiary education, and short cycle tertiary
education; long education included all education levels from
university graduate level and above.
Primary outcome
The primary outcome was negative symptoms measured on the
scale for assessment of negative symptoms.22 The scale contains
five domains, but in line with later factor analyses,30 we only
included the four global domains considered the most robust
and most used in proposed criteria for remission in
schizophrenia31: avolition-apathy, anhedonia, alogia, and
affective blunting. The average of these four scores yielded a
composite negative dimension score ranging from 0 to 5 points.30
Secondary outcomes
1.Remission of both positive and negative symptoms,
reflected as no global scores on the scale for assessment
for positive symptoms22 and exceeding 2 on the scale for
assessment of negative symptoms (that is, mild symptoms)
over the past three months.
2.Similarly to negative symptoms, psychotic symptoms were
measured as the average of two of the four global domains
on the scale for assessment for positive symptoms (global
hallucination and global delusion).22 30
3.Substance abuse was estimated as a reduction in
participants fulfilling criteria for a diagnosis of harmful
use or dependency syndrome diagnosed with ICD-10
(F1x.1 and F1x.2).20 Diagnoses were established using the
schedule for clinical assessment in neuropsychiatry,28
sections 11 and 12.
4.To assess user satisfaction during the study, participants
answered the client satisfaction questionnaire.32
5.Adherence to treatment was assessed first by use of the
Danish National Patient Registry33 to establish whether the
participant had attended a meeting with the case manager
within the last three months of the study. If so, the
participant was considered to be in adherence with
treatment, or still in contact with specialised psychiatric
services. For those participants where the register did not
find any contacts within the last three months before the
follow-up assessment, the medical files were assessed by
an independent investigator. If the registers were found to
be wrong, the adherence status was changed. Owing to
organisational differences, this assessment could be made
only for participants from the five teams in Copenhagen
(n=319).
6.Compliance with medical treatment was measured as the
percentage of full prescribed doses taken in the past week.
Answers were then categorised as 0-25%, 25-50%, 50-75%,
and 75-100% of prescribed doses.
7.Suicidal behaviour, defined as suicidal thoughts in the past
year, was assessed by participant report.
8.By use of data from the Danish National Patient Registry,33
numbers of days in hospital care were calculated.
9.Based on the DREAMdatabase34 from the DanishMinistry
of Employment, the labour market affiliation was assessed.
The database contains data on both employment and use
of social welfare.
The ability to live independently was defined as a secondary
outcome in our trial protocol, but the registers on supported
housing have not been updated yet and this outcome will be
reported later.
Exploratory outcomes
1.Contrary to most SEI treatment programmes, most OPUS
teams also treat patients diagnosed with a schizotypal
disorder. Therefore, for comparability, we also explored
psychotic symptoms after exclusion of participants with
this diagnosis.
2.Disorganised dimension is measured as the average of two
global domains on the scale for assessment for positive
symptoms (global rating of bizarre behaviour and global
rating of positive formal thought disorder) and one item
from the scale for assessment of negative symptoms
(inappropriate affect).30
3.Remission of psychotic symptoms in the past two years
was assessed with the life chart schedule.35
4.Global cognitive functioning was reflected in the brief
assessment of cognition in schizophrenia.36 The raw scores
from this assessment were transformed to z scores at
baseline and follow-up, based on the mean and standard
deviation of the healthy controls from a different Danish
trial,37 and are reported as total z scores.
5.Functional level, on both the global assessment of
functioning38 and personal and social performance scale,39
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were assessed at the follow-up and baseline interview and
the results were the same for both scales. The total score
of the personal and social performance scale is reported.
6.Based on the assessment of compliance with medical
treatment, the proportion of participants receiving
antipsychotic treatment could be evaluated.
7.Doses of antipsychotic drugs were calculated into
chlorpromazine equivalents using Gardner’s consensus
article from 2010.40 For those drugs for which the article
does not provide an algorithm, the World Health
Organization’s defined daily doses were used.41 There is
no consensus regarding the best way to calculate
chlorpromazine equivalents42 and, for sensitivity analyses,
the minimal effective doses were used.43
8.Participants assessed their working alliance with their
contact person using the working alliance inventory.44
9.Self-efficacy was assessed by participant self-report using
the general self-efficacy scale.45
10.Participant’s quality of life was measured on four domains
(physical health, psychological, social relationship, and
environment) in the WHO Quality of Life-BREF
(WHOQOL-BREF).46
11.Outpatient contacts and psychiatric emergency contacts
per year were calculated by use of the Danish National
Patient Registry.33
At the follow-up assessment, the blind was broken in 9.0%
(n=26) of interviews: 7.7% (n=11) in the treatment as usual
group and 10.2% (n=15) in the intervention group.
Inter-rater reliability
All investigators were trained in conducting interviews for the
schedule for clinical assessment in neuropsychiatry at the
CopenhagenUniversity’s PhD course. Similarly, all investigators
were trained in manuals for the scale for assessment for positive
symptoms and scale for assessment of negative symptoms, and
there were regular reliability interviews at the baseline
investigations and during follow-up. The intraclass correlation
coefficients varied from 0.63 to 0.77 for the negative dimension,
indicating good agreement, although still below the study
protocol’s aim of 0.7. For the psychotic dimension, intraclass
correlation coefficients ranged from 0.70 to 0.90, indicating
good to very good agreement.47
Statistical methods
Power calculations
At the two year follow-up in the OPUS I trial, we found a mean
difference of 0.40 points (standard deviation 1.20) on the
negative dimension between the experimental intervention group
and control group.17 In the present trial, we aimed to detect the
same difference, five year after initiation of treatment, and three
years after end of the standard two year SEI treatment. This
meant that we had to recruit 142 participants to each study group
to be able to reject the null hypothesis that the population means
of the two groups were equal with a probability (power) of 0.80.
The type 1 error probability associated with the test of this null
hypothesis is 0.05. Expecting approximately 30% attrition, we
included 200 patients in both the intervention and control groups.
Analysis
All analyses were conducted according to the intention to treat
principle, with a statistician blinded for treatment allocation.
To compensate for missing data, we analysed the data using
multiple imputations, predictive mean matching with nearest
neighbour for the medicine data, linear regression for the rest
of the continuous outcomes, and binary logistic regression for
the dichotomous outcomes. Based on attrition analysis, the data
were not missing completely at random, and assuming that the
rest of the data were missing at random, the multiple imputation
command in SPSS was set to use the baseline values of primary
and secondary outcomes and age, sex, disorganised dimension,
treatment site, and diagnosis as predictor variables when
imputing missing data. The imputed data were all those used to
establish the outcome variables.
A total of 100 datasets were imputed. We analysed the data
using binary logistic regression for the dichotomous variables
(remission, suicidal ideation, diagnosis of substance abuse,
compliance with medical treatment, adherence to treatment,
remission of psychotic symptoms in the last two years of the
study, antipsychotic treatment in the last month, antipsychotic
treatment in the last two years, competitive employment, and
disability pension). We also used linear regression for the
continuous variables (negative dimension, psychotic dimension,
client satisfaction, number of months employed, bed days,
working alliance, general self-efficacy, disorganised dimension,
psychotic dimension excluding schizotypal disorder, total z
score for the brief assessment of cognition in schizophrenia,
personal and social performance scale, doses of antipsychotic
drugs, quality of life, outpatients contacts, and psychiatric
emergency contacts). The stratification variables (treatment site
and negative symptoms) were included as covariants in the
analyses. Owing to uneven distribution of sex and client
satisfaction at baseline, we conducted a sensitivity analysis with
these variables included as covariates. We did all analyses using
SPSS version 22.
Patient involvement
During the development of the trial protocol, the design and
outcomes of the studywere discussedwith the OPUS user panel,
a panel of former service users in OPUS. Participants will
receive written information about the results of the study.
Results
A total of 468 participants were eligible for assessment at the
time of recruitment. After exclusion of those not meeting
inclusion criteria, who moved too far away, or who died, 440
participants were truly eligible for the study and the 400
recruited therefore represents 90.9% of the eligible population.
Baseline characteristics showed a higher proportion of women
in the treatment as usual group and higher client satisfaction
among the participants randomised to extendedOPUS treatment.
Baseline values are reported in table 1⇓. Of those participants
for whom we were able to assess adherence to treatment (the
319 patients treated in Copenhagen), 90.4% randomised to
prolonged treatment remained in OPUS treatment until the end
of the intervention versus 55.6% who remained in contact with
either community health centres or assertive community teams
in the treatment as usual group (P<0.001).
Attrition
The overall attrition of participants can be seen in figure 1⇓. Of
the 400 patients included, 289 were seen at the follow-up
interview. The primary outcome was assessed in 286
participants. Because of attrition at the follow-up interview,
sources for attrition bias had to be considered. We found a
statistically significant difference between participants attending
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follow-up and those not at the negative dimension, disorganised
dimension, treatment site, client satisfaction, and diagnosis.
Those not attending the follow-up interview had higher negative
dimension and disorganised dimension scores and lower client
satisfaction at baseline than those attending. This difference
was corrected for using multiple imputations.
Primary outcome
Both study groups were able to maintain treatment effects from
baseline to follow-up. We found no significant difference
between the intervention group and control group regarding
negative symptoms. Mean negative dimensions for OPUS
participants versus treatment as usual participants were 1.72
versus 1.81 points (estimated mean difference −0.10 (95%
confidence interval −0.33 to 0.13), P=0.39). In sensitivity
analyses of the observed data, the mean was slightly lower,
corresponding to the lower level of baseline negative symptoms
of patients attending the follow-up interview, but the estimated
mean difference and 95% confidence interval was similar.
Secondary and exploratory outcomes
Results for secondary and exploratory outcomes are shown in
tables 2 and 3⇓. Sensitivity analyses of the observed data or
including sex and baseline client satisfaction did not significantly
change the mean difference and 95% confidence interval for
any of the variables.
In the primary analyses, we found no statistically significant
differences between the two treatment groups on mean scores
on the psychotic dimension or on the proportion of participants
in remission. For the psychotic dimension, the mean scores were
1.72 for the OPUS group versus 1.94 for the treatment as usual
group (estimated mean difference −0.23 (95% confidence
interval −0.52 to 0.06), P=0.12; table 2⇓). Exploratory analyses
excluding patients with a schizotypal disorder did not affect the
estimatedmean difference substantially (−0.26 (−0.56 to 0.05),
P=0.10; table 3⇓).
In fact, 22.3% of OPUS participants and 21.7% of treatment as
usual participants were in remission of both negative and
psychotic symptoms (odds ratio 1.08 (95% confidence interval
0.65 to 1.80), P=0.76; table 2⇓). The rates of participants with
a dual diagnosis of substance abuse were lower at the follow-up
assessment than at the baseline interview, but there was no
difference between the OPUS (16.8%) and treatment as usual
(17.2%) groups (0.95 (0.53 to 1.72), P=0.87). Of those
participants receiving antipsychotic treatment, 83% in the OPUS
group versus 79% in the treatment as usual group reported taking
at least 75% of their prescribed doses (odds ratio 1.34 (95%
confidence interval 0.61 to 3.0), P=0.47). For the working
alliance exploratory outcome (estimated mean difference 5.56
(95% confidence interval 2.30 to 8.82), P=0.001; table 2⇓) and
the client satisfaction secondary outcome (2.57 (1.36 to 3.79),
P<0.001; table 3⇓), we found a significant difference favouring
OPUS treatment.
For the register data (tables 2 and 3⇓), all data were available
for all patients. We did not find any significant differences for
number of months employed (estimated mean difference −0.11
(95% confidence interval −2.67 to 2.44), P=0.93) or mean
number of bed days between the OPUS group (9.1 (standard
deviation 21.9)) and treatment as usual group (11.8 (34.1);
estimated mean difference −2.79 (95% confidence interval
−8.40 to 2.82), P=0.33). For exploratory outcomes, we did not
find any differences in disability pensions (28.4% OPUS
treatment v 25.6% treatment as usual; odds ratio 1.18 (95%
confidence interval 0.72 to 1.92), P=0.52)), labour market
affiliation at end of study (23.4% in competitive work or study
v 25.1%; odds ratio 0.92 (95% confidence interval 0.56 to 1.50),
P=0.73), or number of psychiatric emergency contacts (0.48
(standard deviation 1.11) v 0.40 (0.84); estimated mean
difference 0.08 (95% confidence interval −0.11 to 0.27),
P=0.43). As expected, we saw a significantly higher use of
outpatient services in the OPUS group (18.4 (standard deviation
12.0)) contacts per year versus the treatment as usual group
(14.6 (11); estimated mean difference 3.78 (95% confidence
interval 1.56 to 6.01), P=0.001).
Discussion
Principal findings
The ability to affect the negative symptoms in schizophrenia
spectrum disorders has been one of the main accomplishments
of the OPUS treatment, as shown in the OPUS I trial.17 In the
present OPUS II trial, both treatment models compared were
able to maintain the level of negative symptoms, observed at
baseline, and we were not able to find any effects of the
prolonged OPUS intervention on the negative symptoms, nor
on any other psychopathological dimensions, functional level,
labour market affiliation, cognitive function, or hospital
admissions. We did find a positive effect of prolonged OPUS
on the working alliance exploratory outcome, and a higher client
satisfaction in the intervention group. The high rate of
discontinuation from the community health centres is not
considered a central finding because we were unable to properly
assess the reasons for discontinuation.
The lack of treatment benefits of the prolonged treatment could
either be interpreted to mean that the beneficial effects of two
years of treatment can be sustained without needing further SEI
treatment, or that three additional years of treatment do not
improve the outcome of illness. The fact that all participants
improved on their psychopathological scores, cognitive levels,
and functional scores suggests that the first interpretation is the
most accurate (fig 2⇓).
The continued improvement in symptoms is contradictory to
the OPUS I trial,15 in which patients who received OPUS
treatment had a mean relapse of symptoms after the end of SEI
treatment. A plausible explanation for the lack of beneficial
treatment effects and the general improvements seen in the
OPUS II trial could be the high quality of the treatment provided
to the control group. The fact that participants in the control
group had a surprisingly high number of contacts with their case
managers suggests that the treatment provided in both the
intervention and the control group is beneficiary. Furthermore,
elements introduced by SEI services as family involvement and
psychoeducation are now mandatory in the community health
centres. Finally, as many as 19% of participants randomised to
treatment as usual in OPUS II had been in contact with an
assertive community team during follow-up. The caseload in
these teams was 10 patients to one case manager, indicating that
we compared two treatment programmes with equivalent
treatment intensity for the most ill participants. The difference
in symptom improvement between the two studies could also
be due to changes in the treatment provided or the symptoms
of the participants recruited.
One could question whether SEI treatment was provided early
enough to affect the course within the critical period. The mean
duration of untreated psychosis was more than three years
(median 52 weeks). We were aware that some patients were on
waiting lists in the community health centres for up to one year
before starting their OPUS treatment. A patient who had
untreated psychosis for two years and then waited one year
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before starting treatment would be at end of the critical phase
after the regular two years of treatment. Thus, the prolonged
treatment given would mostly have been provided in the plateau
phase,48 which is when the effect of SEI teams is more
questionable. Other studies have found a relation between
duration of untreated psychosis and outcome,49 and one
randomised controlled trial found that shortening the duration
of untreated psychosis had an effect on the long term functional
outcome.50
There are various explanations for the effects seen on the
working alliance and client satisfaction questionnaire, which
indicates a more positive patient experience. In a media climate
where psychiatry is often accused of providing suboptimal
treatment, it is important to state that patients are content with
the treatment that they receive. However, it is also possible that
participants were more interested in being randomised to the
intervention group and, consequently, might have scored these
items better because they received the desired intervention, even
if there was no benefit on the other outcomes.
Strengths and limitations of study
Strengths
We used central randomisation stratifying for important
predictive factors,51-54 used blinded outcome assessors,51-54
assessed several register based outcomes that are likely less
influenced by knowledge about intervention group affiliation
than other outcomes, included stratification factors in our main
analyses,55 56 conducted our main analyses on the data where
missingness was controlled by multiple imputation,57 58
conducted our analyses blinded for intervention group,59 and
drew our conclusions without knowledge of intervention group.59
Moreover, although we based our sample size calculation on a
power of 80%, by inflating our sample by 30% and analysing
all participants using multiple imputations, we actually had a
power of 91% to detect the a priori defined least significant
difference regarding the primary outcome.
Limitations
Owing to the nature of psychosocial interventions, participants
and clinical staff were not blinded. The primary outcome was
negative symptoms, but because the study included participants
with non-psychotic disorder (schizotypal disorder), it was
underpowered to detect small differences on the psychotic
dimension. Furthermore, the need to randomise patients six
months before the start of the intervention could have affected
the last part of the OPUS treatment for the treatment as usual
group. Of 468 participants eligible for inclusion in the study,
11 were transferred to specialist teams such as a dual diagnosis
team or forensic team, or lived in supported housing facilities
with a high staff-to-patient ratio and therefore did not continue
in OPUS treatment. Another 23 eligible participants declined
to participate, and we do not know how these two groups
differed from the studied population.
Follow-up was 72%, which was sufficient, but there was
substantial attrition bias with regard to treatment site, negative
and disorganised dimension, diagnosis, and client satisfaction.
We corrected these differences by using multiple imputations,
setting the number of imputations as high as 100, and calculating
sensitivity analyses for the missing data. However, we do not
know whether the results would have changed without this
attrition. We have no measurement of family or carers’
experience of the intervention, and we believe that inclusion of
their experiences would have provided valuable information.
No measurement of fidelity was included in the study which
makes us unable to report on the treatment actually provided in
the study period, neither were we able to thoroughly assess the
treatment provided to the treatment as usual group.
Adherence to treatment was only measured at the end of the
study and therefore was not a fully adequatemeasurement during
follow-up. To assess the use of outpatient services, we found
the use of registers an inaccurate method to assess adherence
during follow-up, and therefore supplemented our register data
with registrations from themedical files for the last three months
of follow-up. We abstained from using any measurements of
adherence in the follow-up interview because of the risk of
breaking the blind. Finally, the reliance on only two time points
restricted our ability to analyse the course of illness. We chose
only one follow-up point owing to previous problems with high
attrition rates with frequent follow-up points. To compensate
for this, we supplemented our survey data with register data,
which to some degree can be used to analyse the entire follow-up
period.
Comparison with other studies
To our knowledge, this is the first randomised clinical trial
testing prolonged early intervention beyond three years. One
trial compared the effect of three years of SEI with two years
and showed positive effects on functional levels and depressive
and negative symptoms,60 but it was conducted in a low resource
setting. Therefore, the treatment offered in the treatment as usual
groupmight not be comparable to the service level in Denmark.
A Canadian trial is currently testing five years of SEI treatment
compared with two years,61 but results are not yet published.
Conclusion and policy implications
Our data showed a general improvement for both treatment
groups, confirming findings from earlier follow-up studies that
patients diagnosed with schizophrenia do not have an overall
deteriorating course.62-65 Our results differ from previous long
term follow-up studies of SEI treatment where participants seem
to relapse after end of the intervention treatment. But we did
not find an effect of prolonged treatment on our primary
outcome, and therefore the results of the main trial outcomes
cannot serve as a basis for recommending SEI treatment for five
years. However, our results do not contradict the critical phase
hypothesis.
Given the intensity of treatment provided to the treatment as
usual group, we may have found two ways to uphold the
beneficial effects of the two year SEI programme. Either
prolonged early intervention or treatment as usual with assertive
community treatment were provided to the most ill group of
patients. Further trials into prolonged early intervention should
include interventions to reduce treatment delays within the
treatment system and with detection teams to shorten the
duration of duration of untreated psychosis. Further subgroup
analyses of the effect of delay on the treatment effect will be
conducted and published. Secondary economic analyses might
also show no increased cost to the prolonged treatment—if so,
the higher client satisfaction might in itself be an argument for
implementation.
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Tables
Table 1| Baseline characteristics for 400 participants with disorders in the schizophrenia spectrum, included in the Danish OPUS II trial.
Data are number (%) of participants unless stated otherwise
Treatment as usual (n=203)OPUS treatment (n=197)Characteristics
Sociodemographic characteristics
115 (56.7)89 (46.2)Female
25.5 (4.2)25.6 (4.3)Age (mean (SD))
18 (8.9)12 (6.1)Being a parent
78 (38.4)81 (41.1)Completed high school
44 (21.7)33 (16.8)Employed or enrolled as a student
19 (9.4)17 (8.6)Disability pension
Education
86 (42.6)85 (43.1)None
20 (9.9)28 (14.2)Under education
57 (28.2)51 (25.9)Short education, skilled
39 (19.3)33 (16.8)Long education
Living conditions
122 (60.1)110 (55.8)Living alone
38 (18.7)42 (21.3)Living with partner, children, or both
23 (11.3)31 (15.7)Living with parents
15 (7.4)11 (5.6)Living in supervised setting
5 (2.5)2 (1)Homeless
Clinical
Diagnosis
152 (74.9)147 (74.6)Schizophrenia
44 (21.7)39 (19.8)Schizotypal disorder
5 (2.5)5 (2.5)Delusional disorder
1 (0.5)1 (0.5)Brief and transient psychotic disorder
0 (0)4 (2)Schizoaffective disorder
1 (0.5)1 (0.5)Unspecified non-organic psychosis
188 (92.6)180 (91.4)Non-psychotic psychiatric illness before psychosis and OPUS
164 ( 196)121 (173)Duration of untreated psychosis (weeks, mean (SD))
69 (0-879)52 (0-962)Duration of untreated psychosis (weeks, median (range))
1.86 (0.97)1.89 ( 0.93)Negative dimension (mean (SD))
1.82 (1.26)1.92 (1.19)Psychotic dimension (mean (SD))
2.04 (1.28)2.15 (1.17)Psychotic dimension, excluding F21 (mean (SD))
0.44 (0.58)0.52 (0.60)Disorganised dimension (mean (SD))
−2.32 (1.92)−2.47 (1.66)
Total z scores in brief assessment of cognition in schizophrenia (mean
(SD))
45 (22.2)48 (24.4)Substance abuse*
420 (293)463 (332)Chlorpromazine equivalents (mg, mean (SD))
Suicide ideation and behaviour
89 (43.8)71 (36)Suicide attempt ever
16 (7.9)17 (8.6)Suicide attempt in last year of study
105 (52)94 (47.7)Suicidal ideations in last year of study
Social functioning
48.8 (13.5)48.4 (11.7)Personal and social performance scale (score, mean (SD))
Treatment
26.3 (4.4)27.3 (3.9)Client satisfaction at baseline (mean (SD)), CSQ
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Table 1 (continued)
Treatment as usual (n=203)OPUS treatment (n=197)Characteristics
84.7 (10.5)85.6 (11.1)
Duration from start of OPUS treatment to inclusion interview (weeks,
mean (SD))
F21=schizotypal disorder; OPUS treatment=psychosocial treatment programme (specialised early intervention) provided to all patients diagnosed with a schizophrenia
spectrum disorder in Denmark, column namedOPUS show participants randomised to five years of OPUS treatment; SD=standard deviation, CSQ=client satisfaction
questionnaire.
*Fulfilling criteria for harmful use or dependency syndrome diagnosed, ICD-10 (international classification of diseases, 10th revision, F1x.1 and F1x.2).
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Table 2| Primary and secondary outcomes, assessed 3.5 years after inclusion in the OPUS II trial and five years after initiation of SEI
intervention treatment
Imputed and register data
PdifferenceOdds ratio (95% CI)
Estimated mean
difference (95% CI)Treatment as usualOPUS treatmentNo of participants
Primary outcome
0.39—−0.10 (−0.33 to 0.13)1.811.72400
Negative dimension (mean
(SD))
Secondary outcomes
0.12—−0.23 (−0.52 to 0.06)1.941.72400
Psychotic dimension (mean
(SD))
0.761.08 (0.65 to 1.80)—44 (21.7)44 (22.3)400Remission
0.370.80 (0.50 to 1.30)—69 (34.0)58 (29.4)400Suicidal ideation
0.870.95 (0.53 to 1.72)—35 (17.2)33 (16.8)400Substance abuse*
0.471.34 (0.61 to 3.0)—97 (79)89 (83)229
Compliance with medical
treatment†
<0.001—2.57 (1.36 to 3.79)24.427.0400
Client satisfaction (mean
(SD))
0.93—−0.11 (−2.67 to 2.44)9.0 (14.0)8.8 (14.1)400
No of months employed
(mean (SD))‡
0.33—−2.79 (−8.40 to 2.82)11.8 (34.1)9.1 (21.9)400
No of bed days (mean per
year (SD))‡
<0.0018.6 (4.5 to 16)—90 (55.6)142 (90.4)319Adherence to treatment§
Data are number (%) of participants unless stated otherwise. OPUS treatment=psychosocial treatment programme (specialised early intervention) provided to all
patients diagnosed with a schizophrenia spectrum disorder in Denmark, column named OPUS show participants randomised to five years of OPUS treatment;
SD=standard deviation.
*Fulfilling criteria for harmful use or dependency syndrome diagnosed, ICD-10 (F1x.1 and F1x.2).
†Only analysed for participants receiving treatment with antipsychotic drugs.
‡Data based on registers and therefore not imputed.
§Outcome was operationalised as participants were still in contact with specialised psychiatric services at the time of follow-up interview. Data were obtained with
a combination of registers and medical files, and therefore not imputed and only analysed for participants from Copenhagen.
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Table 3| Exploratory outcomes (post hoc analyses), assessed 3.5 years after inclusion in the OPUS II trial and five years after initiation of
SEI treatment
Imputed data and register data
Pdifference
Odds ratio (95%
CI)
Estimated mean
difference (95% CI)
Treatment as
usualOPUS treatment
No of
participants
0.28—−0.11 (−0.29 to 0.084)0.790.69400Disorganised dimension (mean (SD))
0.10—−0.26 (−0.56 to 0.05)2.051.80345
Psychotic dimension, excluding
schizotypal disorders (mean (SD))
0.461.19 (0.75 to 1.87)—84 (41.4)87 (44.4)400
Remission of psychotic symptoms in
last two years
0.88—0.03 (−0.33 to 0.39)−1.89−1.88400
Total z scores in brief assessment of
cognition in schizophrenia (mean (SD))
0.97—−0.06 (−2.89 to 2.77)54.554.2400
Personal and social performance scale
(score, mean (SD))
0.300.78 (0.49 to 1.25)—122 (59.9)108 (54.9)400
Receiving antipsychotic treatment in
last month
0.630.88 (0.53 to 1.46)—148 (73.0)140 (71.0)400
Receiving any antipsychotic treatment
in last 2 years
0.6421.8 (−68.3 to 112)—398423229
Doses of antipsychotic drugs (mean
(SD))*
0.001—5.56 (2.30 to 8.82)60.165.6400Working alliance (mean (SD))
0.29—0.79 (−0.68 to 2.26)26.627.3400General self-efficacy (mean (SD))
Quality of life (four domains)
0.25—2.2 (−1.5 to 6.0)65.167.3400Physical health
0.29—2.6 (−2.2 to 7.4)53.856.2400Psychological
0.66—0.99 (−3.3 to 5.3)61.362.2400Social relationship
0.23—2.2 (−1.4 to 5.8)66.468.4400Environment
0.90—−0.16 (−2.78 to 2.45)12.4 (14.8)12.1 (15.2)400
No of months in some sort of
employment (mean (SD))†
0.730.92 (0.56 to 1.50)—51 (25.1)46 (23.4)400
Patients in competitive employment or
studying at follow-up (%)†
0.790.94 (0.59 to 1.48)—64 (31.5)59 (29.9)400
In study, competitive or non-competitive
employment at follow-up (%)†
0.521.18 (0.72 to 1.92)—52 (25.6)56 (28.4)400
Patients on disability pension at
follow-up (%)†
0.001—3.78 (1.56 to 6.01)14.6 (11.0)18.4 (12.0)400
No of outpatient contacts (mean per
year (SD))†
0.43—0.08 (−0.11 to 0.27)0.40 (0.84)0.48 (1.11)400
No of psychiatric emergency hospital
contacts (mean per year (SD))†
Data are number (%) of participants unless stated otherwise. OPUS treatment=psychosocial treatment programme (specialised early intervention) provided to all
patients diagnosed with a schizophrenia spectrum disorder in Denmark, column named OPUS show participants randomised to five years of OPUS treatment;
SD=standard deviation.
*Only analysed for participants receiving antipsychotic medical treatment at five year follow-up.
†Numbers were based on registers and therefore not imputed.
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Figures
Fig 1 Flowchart of participants in the OPUS II study
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Fig 2 Psychopathological, functional, and cognitive development during the OPUS II study. From top to bottom, graphs
show development of negative symptoms (mean score on the scale for assessment of negative symptoms (SANS)),
psychotic symptoms (mean score on the scale for assessment for positive symptoms (SAPS)), functional level (mean score
on the personal and social performance scale (PSP)), and cognitive functioning (mean total score on the brief assessment
of cognition in schizophrenia (BACS)) from baseline to follow-up
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